Richard J Cassidy1,2, Yuan Liu3, Kirtesh Patel1,2, Jim Zhong1,2, Conor E Steuer2,4, David A Kooby2,5, Maria C Russell2,5, Theresa W Gillespie2,5, Jerome C Landry1,2. 1. Department of Radiation Oncology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 2. Winship Cancer Institute, Emory University, Atlanta, Georgia. 3. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia. 4. Department of Medical Oncology, Emory University, Atlanta, Georgia. 5. Department of Surgery, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Stage II and III rectal cancers have been effectively treated with neoadjuvant chemoradiotherapy (NCRT) followed by definitive resection. Advancements in surgical technique and systemic therapy have prompted investigation of neoadjuvant multiagent chemotherapy (NMAC) regimens with the elimination of radiation (RT). The objective of the current study was to investigate factors that predict for the use of NCRT versus NMAC and compare outcomes using the National Cancer Data Base (NCDB) for select stage II and III rectal cancers. METHODS: In the NCDB, 21,707 patients from 2004 through 2012 with clinical T2N1 (cT2N1), cT3N0, or cT3N1 rectal cancers were identified who had received NCRT or NMAC followed by low anterior resection. Kaplan-Meier analyses, log-rank tests, and Cox-proportional hazards regression analyses were conducted along with propensity score matching analysis to reduce treatment selection bias. RESULTS: The 5-year actuarial overall survival (OS) rate was 75% for patients who received NCRT versus 67.2% for those who received NMAC (P < .01). On MVA, those who received NCRT had improved OS (hazard ratio, 0.77. P < .01), and this effect was confirmed on propensity score matching analysis (hazard ratio, 0.72; P = .01). In the same model, the following variables improved OS: age < 65 years, having private insurance, treatment at an academic center, living in an affluent zip code, a low comorbidity score, receipt of adjuvant chemotherapy, and a shorter interval before surgery (all P < .05). African Americans, men, patients with high-grade tumors, those with cT3N1 tumors, and those who underwent incomplete (R1) resection had worse OS (all P < .05). CONCLUSIONS: In this series, the elimination of neoadjuvant RT for select patients with stage II and III rectal adenocarcinoma was associated with worse OS and should not be recommended outside of a clinical trial. Cancer 2017;123:783-93.
BACKGROUND: Stage II and III rectal cancers have been effectively treated with neoadjuvant chemoradiotherapy (NCRT) followed by definitive resection. Advancements in surgical technique and systemic therapy have prompted investigation of neoadjuvant multiagent chemotherapy (NMAC) regimens with the elimination of radiation (RT). The objective of the current study was to investigate factors that predict for the use of NCRT versus NMAC and compare outcomes using the National Cancer Data Base (NCDB) for select stage II and III rectal cancers. METHODS: In the NCDB, 21,707 patients from 2004 through 2012 with clinical T2N1 (cT2N1), cT3N0, or cT3N1 rectal cancers were identified who had received NCRT or NMAC followed by low anterior resection. Kaplan-Meier analyses, log-rank tests, and Cox-proportional hazards regression analyses were conducted along with propensity score matching analysis to reduce treatment selection bias. RESULTS: The 5-year actuarial overall survival (OS) rate was 75% for patients who received NCRT versus 67.2% for those who received NMAC (P < .01). On MVA, those who received NCRT had improved OS (hazard ratio, 0.77. P < .01), and this effect was confirmed on propensity score matching analysis (hazard ratio, 0.72; P = .01). In the same model, the following variables improved OS: age < 65 years, having private insurance, treatment at an academic center, living in an affluent zip code, a low comorbidity score, receipt of adjuvant chemotherapy, and a shorter interval before surgery (all P < .05). African Americans, men, patients with high-grade tumors, those with cT3N1 tumors, and those who underwent incomplete (R1) resection had worse OS (all P < .05). CONCLUSIONS: In this series, the elimination of neoadjuvant RT for select patients with stage II and III rectal adenocarcinoma was associated with worse OS and should not be recommended outside of a clinical trial. Cancer 2017;123:783-93.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: J E Tepper; M J O'Connell; G R Petroni; D Hollis; E Cooke; A B Benson; B Cummings; L L Gunderson; J S Macdonald; J A Martenson Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: M Kusters; C A M Marijnen; C J H van de Velde; H J T Rutten; M J Lahaye; J H Kim; R G H Beets-Tan; G L Beets Journal: Eur J Surg Oncol Date: 2010-01-21 Impact factor: 4.424
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: Alexis Vallard; Max-Adrien Garcia; Peng Diao; Sophie Espenel; Guy de Laroche; Jean-Baptiste Guy; Majed Ben Mrad; Chloé Rancoule; David Kaczmarek; Thierry Muron; Gregoire Pigné; Jack Porcheron; Michel Peoc'h; Jean-Marc Phelip; Julien Langrand-Escure; Nicolas Magné Journal: Oncotarget Date: 2018-04-27
Authors: Hamid Nasrolahi; Sepideh Mirzaei; Mohammad Mohammadianpanah; Ali Mohammad Bananzadeh; Maral Mokhtari; Mohammad Reza Sasani; Ahmad Mosalaei; Shapour Omidvari; Mansour Ansari; Niloofar Ahmadloo; Seyed Hasan Hamedi; Nezhat Khanjani Journal: Ann Coloproctol Date: 2019-10-31